We describe 2 cases of a distinct sarcoma characterized by a novel MEIS1-NCOA2 gene fusion. This gene fusion was identified in the renal neoplasms of 2 adults (21-y-old male, 72-yold female). Histologically, the resected renal neoplasms had a distinctively nodular appearance, and while one renal neoplasm was predominantly cystic, the other demonstrated solid architecture, invasion of perirenal fat, and renal sinus vasculature invasion. The neoplasms were characterized predominantly by monomorphic plump spindle cells arranged in vague fascicles with a whorling pattern; however, a more primitive small round cell component was also noted. Both neoplasms were mitotically active and one case showed necrosis. The neoplasms did not have a distinctive immunohistochemical profile, though both labeled for TLE1. The morphologic features are distinct from other sarcomas associated with NCOA2 gene fusions, including mesenchymal chondrosarcoma, congenital/infantile spindle cell rhabdomyosarcoma, and soft tissue angiofibroma. While we have minimal clinical follow-up, the aggressive histologic features of these neoplasms indicate malignant potential, thus warranting classification as a novel subtype of sarcoma.
P erhaps more than any other visceral organ, the kidney is the site of origin of many translocation-associated sarcomas, which follow closely the paradigm seen in soft tissue tumors. Many of these neoplasms present in children and young adults, though a smaller proportion does affect adults. Some examples of translocation associated sarcomas which present as primary renal neoplasms include cellular congenital mesoblastic nephroma/infantile fibrosarcoma, [1] [2] [3] Ewing sarcoma/primitive neuroectodermal tumor, 4, 5 synovial sarcoma, 6 sclerosing epithelioid fibrosarcoma, 7 desmoplastic small round tumor, 8 clear cell sarcoma/melanoma of soft parts, 9 and Xp11 translocation perivascular epithelioid cell tumor (PEComa)/melanotic Xp11 translocation renal cancer. 10, 11 More recently, a subset of renal sarcomas which overlap with clear cell sarcoma of the kidney (CCSK) have been shown to harbor BCOR-CCNB3 12 or YWHAE-NUTM2B 13 gene fusions rather than the BCOR internal tandem duplication 14 harbored by most cases of CCSK. Despite these advances, many primary renal sarcomas remain unclassified.
In this report we describe 2 cases of primary renal sarcoma harboring a novel MEIS1-NCOA2 gene fusion. Their distinctive shared morphologic features and distinct gene fusion support the idea that they represent a novel sarcoma entity.
METHODS Cases
The 2 renal cases reported herein were retrieved from the consultation files of 2 authors (P.A. and V.E.R.). Cases were identified during a review of unclassified primary renal sarcomas, which was aimed at identifying those with BCOR-CCNB3 gene fusion. 12 A total of 22 such cases were studied. Case one was sent for RNA-sequencing which revealed a MEIS1-NCOA2 gene fusion candidate. This result was validated with fluorescence in situ hybridization (FISH) using custom bacterial artificial chromosomes (BAC) probes, showing break-apart signals in both MEIS1 and NCOA2 genes. The remaining cases were then screened by FISH to identify potential NCOA2 gene fusions. This resulted in the identification of case#2, which was shown by FISH to harbor NCOA2 and MEIS1 gene rearrangements.
Fluorescence In Situ Hybridization
FISH on interphase nuclei from paraffin-embedded 4 µm sections was performed applying custom probes using BAC, covering and flanking genes that were identified as potential fusion partners in the RNA-seq experiment. BAC clones were chosen according to UCSC genome browser (http://genome.ucsc.edu) (Supplementary Table 1 DNA from individual BACs was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with DAPI in an antifade solution, as previously described. 15 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with incomplete set of signals were omitted from the score.
RNA Sequencing
RNA was extracted from formalin-fixed paraffinembedded tissue using Amsbio's ExpressArt FFPE Clear RNA Ready kit (Amsbio LLC, Cambridge, MA). Fragment length was assessed with an RNA 6000 chip on an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA-sequencing libraries were prepared using 20 to 100 ng total RNA with the TruSight RNA Fusion Panel (Illumina, San Diego, CA). Each sample was subjected to targeted RNA sequencing on an Illumina MiSeq at 8 samples per flow cell (∼3 million reads per sample). All reads were independently aligned with STAR (version 2.3) and BowTie2 against the human reference genome (hg19) for Manta-Fusion and TopHat-Fusion analysis, respectively.
For comparison of mRNA expression profiles, we included 2 mesenchymal chondrosarcomas with known HEY1-NCOA2 gene rearrangements, and one soft tissue angiofibroma with a known AHRR-NCOA2 gene fusion. In addition, unsupervised clustering was performed including the renal index case (case 1), 3 other control cases with NCOA2 gene fusions (2 mesenchymal chondrosarcomas, 1 soft tissue angiofibroma), and over 100 other sarcomas available on the same targeted RNA-sequencing platform. 16 Other Neoplasms Tested for MEIS1-NCOA2 Fusion by FISH We studied additional tumor types which could potentially be related to the current cohort of MEIS1-NCOA2 positive sarcomas. First, we investigated a group of 11 typical adult mixed epithelial stromal tumor/cystic nephroma (MEST/CN) and 2 pediatric CN, which were previously described in detail in a recent study from our group. 17 The adult MEST/CN occurred in females with an age range of 11 to 73 years, and had the typical morphologic features of MEST/ CN, including cellular stroma, wavy collagen, and estrogen receptor immunoreactivity. 17 The 2 pediatric CN occurred in males 1 and 2 years of age. Second, we also studied 4 cases of mesenchymal chondrosarcoma and 1 angiofibroma with proven NCOA2 gene rearrangements but unknown partner from the consultation files of one author (C.R.A.).
RESULTS

Clinical History and Gross Appearance
Case 1 was a 72-year-old female with cystic left renal tumor that was removed by partial nephrectomy. The neoplasm proved to be a 4 cm complex cyst with an average wall thickness of 1 mm, but with multiple clear to yellow-tan excrescences projecting within cyst lumens. Margin status was unclear as the specimen was received with a defect that connected to the cyst. At 9 months follow-up, there is no evidence of recurrent disease.
Case 2 was a 21-year-old male who was found to have a 15 cm left renal mass and underwent radical nephrectomy. One sectioning, the neoplasm was pale-tan to white, and was solid, nodular, and friable with multiple areas of necrosis and hemorrhage. The tumor involved an area of disruption at the capsular margin. The patient was lost to follow-up.
MEIS1-NCOA2 Positive Renal Neoplasms Show a Primitive Spindle Cell Phenotype With a Distinctive Whorling and Nodular Pattern and Nonspecific Immunoprofile
The most distinctive feature of the resected renal neoplasms was their nodular growth pattern. This was created by spindle cells arranged in short fascicles with a distinct whorling pattern (Figs. 1, 2) . The spindled cells were monomorphic, short, and plump with scant amounts of pink cytoplasm. A population of more primitive rounded cells was also present, typically centered on capillary vasculature.
While the most common phenotype of the neoplastic cells was that of a plump spindle cell, variant patterns were present in each case. Case 2 additionally had an epithelioidround cell component, raising the differential of a primitive round cell sarcoma. Homer Wright pseudorosette-like structures were noted reminiscent of primitive neuroectodermal tumor (Fig. 2G) . Case 1 had better formed fascicles composed of elongated spindled cells in a fibrous background, mimicking the appearance of monophasic synovial sarcoma (Fig. 1C) . Both neoplasms entrapped native renal tubules at their periphery. In case 1, this was the dominant appearance, such that the lesion presented as multicystic mass. The neoplastic spindle cells surrounded cystically dilated entrapped native renal tubular epithelium; the latter frequently had a hobnail appearance characterized by prominent eosinophilic cytoplasm and apically oriented, enlarged nuclei with vesicular chromatin, suggesting the possibility of malignant transformation of MEST/CN (Fig. 1G) . In other areas, the spindle neoplastic cells concentrically surrounded nondilated native renal tubules, of creating an onion-skin pattern similar to that described in renal metanephric stromal tumor (MST) 18 (Fig. 1H) . In case 2, only focal microscopic dilation of entrapped renal tubules was evident at the periphery of the lesion (Fig. 2H) . Instead, this lesion was predominantly solid and had more aggressive growth pattern featuring hemorrhage, necrosis, and renal sinus vascular invasion along with perinephric fat invasion approaching the adrenal gland (Figs. 2I, J) .
The immunohistochemical profiles were not specific. By immunohistochemistry, both neoplasms labeled for CD56 and BCL2. CD99 showed diffuse but nonspecific cytoplasmic staining. Both neoplasms demonstrated focal labeling for WT-1 (nuclear), TLE1, synaptophysin, estrogen receptor, and cyclin D1. Of note, the extent of labeling for TLE1 and cyclin D1 was greater in case 1 (50% to 60%) than in case 2 (5% to 10%).
Both neoplasms were negative for PAX8, myogenin, actin, inhibin, S100, CD34, HMB45, cytokeratin, and GFAP. Desmin labeled only rare cells in case 1 and was completely negative in case 2. Of note, the entrapped renal tubules and cysts of case 1 labeled as expected for PAX8. BCOR was immunoreactive in case 1 in ∼60% of neoplastic cells with moderate intensity, but was negative in case 2. SATB2 labeled rare cells in case 1 but not case 2.
RNA Sequencing
In case 1 (the index case), RNA sequencing identified 2 different fusion transcript variants, equally expressed, in which MEIS1 exon 7 fused to either NCOA2 exon 13 or 14 (Figs. 3A, B) .
Fluorescence In Situ Hybridization
FISH analysis confirmed MEIS1-NCOA2 renal sarcoma case 2, showing break-apart signal in both NCOA2 and MEIS1 genes (Fig. 4) . FISH analysis also validated the RNA sequencing candidate fusions in MEIS1-NCOA2 renal sarcoma case 1 (not shown). 
MEIS1-NCOA2 Positive Kidney Sarcoma Grouped Closely to HEY1-NCOA2 Positive Mesenchymal Chondrosarcomas by Unsupervised Clustering of RNA Sequencing
By unsupervised hierarchical clustering, the renal MEIS1-NCOA2 sarcoma case 1 grouped together with the 2 mesenchymal chondrosarcomas harboring HEY1-NCOA2 available on the same targeted RNA sequencing platform, and away from one soft tissue angiofibroma with AHRR-NCOA2 fusion (Fig. 3C) . The MEIS1 gene was not one of the targeted genes included in the RNA sequencing panel and thus we were not able to evaluate the MEIS1 mRNA expression in our cohort. However, both HEY1 and AHRR genes were included in the panel, and showed a high level of expression in both mesenchymal chondrosarcoma and soft tissue angiofibroma, respectively, but not in the renal MEIS1-NCOA2 sarcoma case 1 (Fig. 3D) . Furthermore, we investigated the differential expression of NCOA2 gene, which showed high expression of 3′NCOA2 exons participating in the fusion (exons 13 to 23) in tumors showing NCOA2 gene fusion regardless of its partners (Fig. 3E) .
Given the known fusion of HEY1 and NCOA2 in mesenchymal chondrosarcoma, 19 we sought to determine if some mesenchymal chondrosarcomas have MEIS1 rather than HEY1 as the NCOA2 partner. However, none of the 4 mesenchymal chondrosarcomas with known NCOA2 gene rearrangement demonstrated MEIS1 gene rearrangements.
Mixed Epithelial Stromal Tumor of the Kidney/ Cystic Nephroma do not Harbor MEIS1-NCOA2 Gene Fusions
Given the extensively cystic appearance of MEIS1-NCOA2 renal sarcoma case 1, along with the complex patterns of entrapped native renal tubules within the lesion, one diagnostic consideration was that of a sarcoma arising within a MEST/CN. Therefore, we examined a group of 11 typical MEST/CN along with 2 pediatric CN for MEIS1-NCOA2 gene fusions by FISH. However, none of these neoplasms demonstrated evidence of NCOA2 or MEIS1 gene rearrangements.
DISCUSSSION
We describe what we believe to be a novel subtype of sarcoma involving the kidney in 2 adult patients. The neoplasm characteristically demonstrates nodular variations in cellularity with distinctive whorling of the monomorphic spindle cells with pale eosinophilic cytoplasm. In addition a variable component of primitive small round cells was also noted showing a perivascular distribution. Most significantly, these 2 morphologically similar neoplasms demonstrate an identical, previously undescribed MEIS1-NCOA2 gene fusion.
The NCOA2 (nuclear receptor co-activator 2) gene is located on chromosome 8q13, and encodes for a nuclear hormone receptor transcriptional co-activator. 20, 21 NCOA2 interacts with ligand-bound receptors to recruit histone acetyltransferases and methyltransferases to facilitate chromatin remodeling and transcription. NCOA2 has previously been implicated as a 3′ partner in gene fusions in sarcomas and leukemias (see below), in which the C-terminal transcriptional activation domains 1 and 2 have been consistently retained in the predicted fusion proteins. Hence, the postulated consequence of these translocations is that NCOA2 is aberrantly targeted by a novel DNA-binding domain contributed by its N-terminal partner. 19 While occasional cases of acute myeloid leukemia have been associated with either MYST3-NCOA2 22 or ETV6-NCOA2 23 gene fusion, a larger number of mesenchymal neoplasms have been shown to be associated with NCOA2 gene fusions. The main differential diagnostic consideration for our MEIS1-NCOA2 renal sarcomas is that of an unusual mesenchymal chondrosarcoma which harbors an alternative MEIS1-NCOA2 gene fusion rather than the cannonical HEY1-NCOA2 gene fusion that most mesenchymal chondrosarcomas harbor. Several lines of evidence argue against this alternative possibility. First, the cytology of the MEIS1-NCOA2 renal sarcomas is that of a monotonous spindle neoplasm rather than primitive small blue round cells seen in mesenchymal chondrosarcoma (Fig. 5) . Second, mesenchymal chondrosarcoma is consistently negative for TLE1 by immunohistochemistry, 24, 25 while both of our MEIS1-NCOA2 renal sarcomas were positive. Third, we found no evidence of MEIS1 rearrangement in a group of mesenchymal chondrosarcomas with confirmed NCOA2 gene rearrangement.
NCOA2 gene fusions are also characteristic of congenital/infantile spindle cell rhabdomyosarcoma, with various partners, including VGLL2, SRF, or TEAD1, which represent critical transcription factors or coactivators involved in muscle development and regulation. 26, 27 Of note, NCOA2 fusion-positive infantile spindle cell rhabdomyosarcomas have a favorable prognosis compared with the older childhood and adult sclerosing/spindle cell rhabdomyosarcomas associated with MYOD1 mutations. 28 Rare cases of alveolar rhabdomyosarcoma have been associated with PAX3-NCOA2 gene fusions. 29 While one of our MEIS1-NCOA2 renal sarcomas demonstrated rare desmin-positive cells, the rhabdomyosarcomas referred to above consistently label for muscle markers such as myogenin and actin and label more diffusely for desmin.
Another soft tissue tumor recently shown to harbor recurrent NCOA2 gene rearrangements is the so-called soft tissue angiofibroma, characterized by an AHRR-NCOA2 gene fusion, with occasional cases demonstrating a GTF21-NCOA2 gene fusion. [30] [31] [32] [33] [34] Soft tissue angiofibroma typically occurs in adult females, and features bland spindle cells associated with prominent thin-walled hemangiopericytomatous vessels with fibrinoid change and thick collagen. Soft tissue angiofibroma lacks the overt sarcomatous appearance of MEIS1-NCOA2-positive renal tumors, while the latter lacks the characteristic vasculature of soft tissue angiofibroma.
In the current neoplasms, the NCOA2 partner is MEIS1, which encodes for a 390 amino acid protein, located at chromosome 2p14. MEIS1 is a member of the three amino acid loop extension (TALE) homeodomain transcription factor family, and is thought to activate target genes by association with Hox transcription factors. MEIS1 stands for "myeloid ectopic viral integration site-1" and its overexpression, induced by retroviral integration, leads to myeloid leukemia. MEIS1 is thought to have roles in cardiac regeneration, stem cell function and tumorigenesis. 35, 36 In some neoplasms such as clear cell renal cell carcinoma, prostatic adenocarcinoma and esophageal squamous cell carcinoma, 37, 38 MEIS1 functions as a tumor suppressor whereas in others it functions as an oncogene. Along these lines, MEIS1 is known to be amplified in a subset of malignant peripheral nerve sheath tumors 39 and neuroblastomas, 40 overexpressed in ovarian cancers, 41 and act as co-factor with HOXA9 in driving acute leukemias, particularly aggressive MLL-associated leukemias 42 and chemotherapy-resistant leukemias. [43] [44] [45] MEIS1 has not previously been associated with chromosome translocations and resulting gene fusions in cancer.
While the partners of NCOA2 in congenital/infantile spindle cell rhabdomyosarcoma (SRF, VGLL-2, and TEAD1) are genes that are normally expressed skeletal muscle, MEIS1 is broadly expressed in a variety of human tissues, and therefore its tissue distribution would not account for preferential localization of this neoplasm in the kidney. Indeed, along these lines we found no evidence of expression of renal specific immunohistochemical markers (such as PAX8) in our renal neoplasms.
Within the kidney, the differential diagnosis of the MEIS1-NCOA2 sarcomas is broad. The BCOR-CCNB3 renal sarcomas 12 which overlap with CCSK have the greatest degree of morphologic overlap with the MEIS1-NCOA2 sarcomas. Both neoplasms feature evenly placed, plump spindle cells with a regular capillary vascular pattern, and both label for immunohistochemical markers such as TLE1. One of our MEIS1-NCOA2 renal sarcomas was positive for BCOR: 46 while this neoplasm demonstrated moderate-strong reactivity in ∼60% of nuclei, it was less than the diffuse strong labeling typically seen in sarcomas harboring BCOR genetic alterations, such as BCOR internal tandem duplication or the BCOR-CCNB3 gene fusion. 47, 48 Aside from genetics, the key morphologic feature of the MEIS1-NCOA2 neoplasms is the nodular variation in cellularity associated with spindle cell whorling and clustering of the small cells. Some areas of the MEIS1-NCOA2 renal sarcomas are morphologically identical to the appearance of monophasic synovial sarcoma, and both may label for BCOR and TLE1. Aside from the distinctive SS18-SSX gene fusions, renal synovial sarcoma typically demonstrates more elongated, hyperchromatic nuclei, and lacks the nodular variations in cellularity seen in the MEIS1-NCOA2 renal sarcomas. The nodularity and focal onionskin pattern noted raised the differential diagnosis of MST. 18 However, MST typically labels for CD34, and demonstrates characteristic features (such as angiodysplasia, glial-epithelial complexes) not seen in the 2 MEIS1-NCOA2 renal sarcomas. The recently described CIC-rearranged renal sarcomas 49 also enter into the differential diagnosis, and these may also be immunoreactive for WT1 in ∼50% of cases. The CIC-associated sarcomas typically have more variable round to epithelioid cell cytology, prominent nucleoli and myxoid matrix. The primitive solid areas of case #2 raise the differential diagnosis of a Ewing sarcoma/primitive neuroectodermal family tumor, but the spindling as well as absence of diffuse membranous CD99 immunoreactivity excluded that possibility. The predominantly cystic appearance of case 1 raised the differential diagnosis of biphasic cystic renal neoplasms including MEST/CN 50 and angiomyolipoma with epithelial cysts (AMLEC). 51 However, the former are associated with more diffuse immunoreactivity for estrogen receptor than is seen in the current cases, demonstrate "ovarian-like," cellular stroma with wavy collagen which is immunoreactive for inhibin in most cases, and are typically immunoreactive for muscle markers. None of the MEST/CN cases tested demonstrated NCOA2 gene rearrangements. Unlike the MEIS1-NCOA2 sarcomas, angiomyolipoma with epithelial cysts labels for melanocytic markers such as HMB45 and Melan A.
In summary, we describe a distinctive sarcoma subtype in the kidney harboring novel MEIS1-NCOA2 gene fusions, characterized by plump spindle cells with variable amounts of eosinophilic cytoplasm demonstrating prominent nodular variations in cellularity. Further studies will be needed to determine the full clinicopathologic and morphologic spectrum of this distinctive neoplasm. We have minimal clinical follow-up in these cases. However, the primitive cytology and mitotic activity of both cases, along with the cellular necrosis, vascular invasion and perinephric fat invasion demonstrated by case 2, strongly suggests that they have malignant potential.
